VC Firm S32 Names Verily Founder Andy Conrad General Partner

Venture capital firm S32 named Andy Conrad as general partner.

Conrad brings experience and expertise in technology and advanced data science, having previously held senior roles at Google, S32 said in a Thursday (Feb. 22) press release. He founded Verily Life Sciences (formerly known as Google Life Sciences).

Before his time at Google, Conrad served as the chief scientific officer of Laboratory Corporation of America (Labcorp) and co-founded the National Genetics Institute, which was later acquired by Labcorp, according to the release. His background includes a doctorate from the University of California, Los Angeles.

S32 already has Google leaders like Bill Maris, who founded the venture capital firm after founding and serving as CEO of Google Ventures, and CEO Andy Harrison, who also has roots in the tech industry, the release said.

“S32 has an extraordinary platform, and I am excited to join the team and work with entrepreneurs growing businesses aimed at improving the human condition,” Conrad said in the release.

Conrad’s focus on enterprise software, artificial intelligence, health technology and computational biology aligns with S32’s mission to invest in technologies across various sectors of the economy, according to the release. The firm has invested in companies like Coinbase and Crowdstrike.

S32 closed its $525 million Fund 5 earlier this year and now has total assets under management reaching $2 billion, the release said.

Maris said in the release that Conrad’s past contributions at Google will be an asset to S32. Harrison emphasized Conrad’s track record as a founder and business builder, stating that he will work on behalf of entrepreneurs and investors.

Verily, which Conrad founded and for which he served as CEO and executive chairman, is a health technology company that has focused on real-world evidence generation, healthcare data platforms, research and care.

It was reported in September that the healthcare sector is projected to nearly double its spending on AI and machine learning, with the share of health company budgets allocated to the technology expected to rise to 10.5% in 2024.